The drug is approved for the treatment of COVID-19 in adult patients and adolescents aged 12 years and older, whose weight exceeds 40 kg.
The US Food and Drug Administration (FDA) has approved the emergency use of an experimental drug for the treatment of the coronavirus Sotrovimab (VIR-7831) produced by the British pharmaceutical company GSK and its American partner Vir Biotechnology.
This is stated in a message on the website of FDA.
вЂњSotrovimab belongs to a class of drugs called monoclonal antibodies that mimic the natural antibodies that the body produces to fight infection,вЂќ the regulator said.
The new drug is approved for the treatment of COVID-19 in adult patients and adolescents aged 12 years and older, whose weight exceeds 40 kg.
However, the drug cannot be used to treat patients with severe COVID-19 who require oxygen therapy. It is allowed only for cases of mild and moderate severity.
At the moment, two drugs with a similar principle of action have already been registered in the United States. One of them is from Regeneron Pharmaceuticals, which was treated for the coronavirus by former US President Donald Trump.
Recall, the American company Pfizer is working on creating a drug for COVID-19 in the form of tablets, which can be ready this year if the tests are successful.
We also reported that the Japanese Ministry of Health has approved the use of the rheumatoid arthritis drug Baricitinib for the treatment of patients with COVID-19.